INSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Insmed Inc (INSM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, and bullish technical indicators make it a solid choice for long-term investment.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (0.942), and RSI_6 at 39.574 in the neutral zone. The price is currently below the pivot level (154.744), with key support at 145.431 and resistance at 164.057. These indicators suggest a potential upward trend in the long term.
Strong revenue growth in Q4 2025 (up 152.62% YoY) and improved gross margin (82.51%).
Positive analyst sentiment with multiple buy/outperform ratings and high price targets (e.g., $204-$231).
Brinsupri's strong market launch trajectory and FY26 revenue guidance of $1B+.
Bullish technical indicators and a 70% chance of price increase in the next month.
Net income remains negative (-$328.49M), though improving YoY.
Post-market price decline of -0.80% and market close below the pivot level.
In Q4 2025, revenue increased by 152.62% YoY to $263.84M. Net income improved by 39.46% YoY but remains negative at -$328.49M. EPS improved by 17.56% YoY to -1.54. Gross margin increased to 82.51%, up 11.88% YoY, reflecting strong operational efficiency.
Analysts are highly positive on INSM, with multiple buy/outperform ratings and price targets ranging from $157 to $231. Analysts highlight strong Brinsupri launch performance, potential market expansion, and robust revenue guidance as key drivers for long-term growth.
